Sabin Vaccine Institute Receives $35 Million from BARDA with Potential of up to $214 Million for Ebola Sudan and Marburg Vaccines

WASHINGTON, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded Sabin a multi-year contract with funding potential for up to $214 million to advance the development and production of single-dose vaccine candidates for Ebola Sudan and Marburg virus diseases.

There are currently no licensed vaccines against Ebola Sudan and Marburg viruses, which cause hemorrhagic fever and kill approximately half the people infected.

BARDA, part of the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response (ASPR), will initially invest approximately $35 million to produce up to 100,000 doses of Sabin’s Ebola Sudan virus (ChAd3-SUDV) vaccine. These vaccines may be used as part of ongoing U.S. preparedness efforts and in response to future global outbreaks.

The Sabin vaccine was the first to arrive in Uganda during the recent Ebola Sudan virus outbreak that caused 55 deaths after the World Health Organization included it as one of three vaccines for possible use in an outbreak trial in Uganda. The country declared the Ebola Sudan outbreak had ended on January 11, four months after the first confirmed case.

“Sabin successfully delivered Ebola Sudan vaccine doses to Uganda within 79 days of the start of the outbreak – quite an impressive accomplishment,” says Sabin Chief Executive Officer Amy Finan. “This new contract enables Sabin to produce up to 100,000 doses so the world is prepared in advance for future outbreaks.”

In addition to participating in recent outbreak activities, Sabin continues its Sudan development plan and has initiated Phase 2 clinical trial planning in Uganda and Kenya. Based on previous clinical trials, Sabin’s Ebola Sudan vaccine is safe and immunogenic, and in nonhuman primate studies has demonstrated rapid protection, durability up to 12 months, and efficacy.

In addition to Sabin’s ChAd3-SUDV vaccine, the contract also includes support to manufacture Sabin’s vaccine against Marburg virus (ChAd3-MARV), which would generate doses that could also be used in trials and in response to a possible Marburg virus outbreak. As recently as last July, two people in Ghana died after being infected with Marburg virus, reinforcing the urgent need for a vaccine.

The new contract leverages a partnership with BARDA that began in 2019, when the agency awarded Sabin another multi-year contract valued at $128 million to further the development of vaccines against both the Marburg and Ebola Sudan viruses.

“BARDA has been a supportive partner as we take these essential steps in pandemic preparedness,” said Finan. “The Ebola Sudan outbreak in Uganda underscored the critical need for readily available solutions. We’ll now have ample material to respond quickly to such an outbreak in the future.”

This project will be funded in whole with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50123C00010.

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with three decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on Twitter, @SabinVaccine.

About Ebola Sudan and Marburg

Ebola Sudan and Marburg are members of the filovirus family. Both can cause severe hemorrhagic fever in humans and nonhuman primates. No therapeutic treatment of these hemorrhagic fevers has been licensed to date. Marburg and Ebola viruses are transmitted to humans by infected animals, particularly fruit bats. Once a human is infected, the virus can spread to others through close personal contact or contact with bodily fluids. Isolation of infected people is currently the centerpiece of filovirus control.

Marburg was the first filovirus to be recognized in 1967 when outbreaks of hemorrhagic fever were reported in a few Europe-based laboratories including in the town of Marburg, Germany. Ebola was identified in 1976 when two simultaneous outbreaks occurred in northern Zaire (now the DRC) in a village near the Ebola River and in southern Sudan. The outbreaks involved what eventually proved to be two different species of Ebola virus; both were named after the nations in which they were discovered.

For media inquiries:

press@sabin.org

Media Contact:
Monika Guttman
Media Relations Specialist
Sabin Vaccine Institute
+1 (202) 662-1841
press@sabin.org

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/539c9127-e5d6-4b32-9e89-780f7461314b


Sabin Vaccine Institute Receives $35 Million from BARDA with Potential of up to $214 Million for Ebola Sudan and Marburg Vaccines

THỦ THUẬT HAY

Hướng dẫn dùng Preview để chỉnh sửa tập tin PDF trên macos

Tuy nhiên, việc chỉnh sửa nội dung trong tài liệu PDF thường gây khó khăn cho người dùng và yêu cầu họ phải sử dụng các phần mềm từ hãng thứ ba, đơn cử như Adobe Acrobat Reader,…

Hướng dẫn cài đặt bản YouTube có thể phát nhạc khi tắt màn hình, chặn hoàn toàn quảng cáo

YouTube hiện đang là dịch vụ lưu trữ và chia sẻ video phổ biết nhất hiện nay. Không chỉ tiện lợi bởi khả năng hoạt động đa nền tảng mà còn phong phú về nội dung cung cấp tới người dùng.

7 trình duyệt web đặc biệt có lẽ bạn chưa từng khám phá

Top 7 trình duyệt đặc biệt mà có thể bạn chưa từng khám phá dưới đây mang đến cho bạn trải nghiệm duyệt web độc đáo mà bạn không thể tìm thấy trên những trình duyệt phổ biến.

Nâng cao trải nghiệm xem Youtube với 3 mẹo cực hay

Youtube là mạng xã hội video lớn và phổ biến nhất hiện nay, bạn có thể tìm kiếm bất kỳ thứ gì mình muốn tại đây. Và để có những trải nghiệm tốt...

10 cách tiết kiệm dữ liệu 3G trên Android

Trình tiết kiệm dữ liệu trên trình duyệt Chrome giúp tiết kiệm 51% dữ liệu, nên khi bật tính năng này lên sẽ giúp tiết kiệm đáng kể lưu lượng dữ liệu khi duyệt web. Để kích hoạt bạn mở trình duyệt Chrome lên, nhấn vào

ĐÁNH GIÁ NHANH

Đánh giá nhanh Sony XA2 Ultra mới xem có gì "ngon"

Cũng như bất kỳ sản phẩm nào của Sony, Xperia XA2 Ultra vẫn không ngoại lệ khi giữ cho mình vẻ đẹp'truyền thống' trong phong cách thiết kế.

Đánh giá camera sau Galaxy J8: Đáp ứng hầu hết nhu cầu chụp ảnh của các bạn trẻ hiện nay

Trước hết hãy lướt qua một chút về cấu hình của camera trên Galaxy J8, thiết bị sở hữu cụm camera kép phía sau với 1 cảm biến ảnh 19MP và 1 cảm biến đạt độ phân giải 5MP, cả hai đều có khẩu độ lớn F/1.9, mang lại khả

Trên tay Sony SBH24: Tai nghe Bluetooth nhỏ gọn, cổng sạc USB-C

Về thông số kỹ thuật, SBH24 không quá nổi bật so với các mẫu tai nghe cùng tầm giá. Ngay cả chuẩn truyền dữ liệu aptX cũng chưa được Sony đưa vào sản phẩm này.